Author:
Kaskas Amir,Clavijo Paul,Friedman Jay,Craveiro Marco,Allen Clint T.
Funder
American Association for Dental, Oral, and Craniofacial Research
National Cancer Institute
National Institute on Deafness and Other Communication Disorders
National Institutes of Health
Colgate-Palmolive Company
Subject
Cancer Research,Oncology,Oral Surgery
Reference38 articles.
1. Phenotypic plasticity and reduced tissue retention of exhausted tumor-infiltrating T cells following neoadjuvant immunotherapy in head and neck cancer;Sievers;Cancer Cell,2023
2. Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy;Luoma;Cell,2022
3. Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter;Uppaluri;Phase II Trial Clin Cancer Res,2020
4. Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial;Schoenfeld;JAMA Oncol,2020
5. Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8(+) Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results;Ferrarotto;Clin Cancer Res,2020